Ooi Setthasorn Zhi Yang, de Koning Rosaline, Egiz Abdullah, Dalle David Ulrich, Denou Moussa, Tsopmene Marvin Richie Dongmo, Khan Mehdi, Takoukam Régis, Kotecha Jay, Sichimba Dawin, Dokponou Yao Christian Hugues, Kanmounye Ulrick Sidney, Bankole Nourou Dine Adeniran
Research Department, Association of Future African Neurosurgeons, Yaounde, Cameroon.
Ibn Sina Teaching Hospital, Rabat Morocco/Mohammed V University of Rabat Morocco, Department of Neurosurgery, Rabat, Morocco.
Int J Surg Protoc. 2022 Feb 2;26(1):1-6. doi: 10.29337/ijsp.171. eCollection 2022.
Over the last decade, many advancements have been made in the management of low-grade gliomas (LGGs). Overall survival outcomes are correlated with factors such as postoperative residual volumes and specific tumor biomolecular profiles such as IDH mutation status. It is unclear whether these advancements have benefited LGG patients in Africa. This scoping review protocol outlines how the authors will evaluate the epidemiology, presentations, management and outcomes of LGGs in Africa.
MEDLINE, Embase and African Journals Online will be searched from database inception to date in order to identify the relevant studies. Patients of all ages with histologically and/or radiologically confirmed LGGs that were managed in an African country will be included. Surgical and chemoradiation management of LGG tumours will be considered. Original research, reviews, commentaries, editorials and case reports will be included.
Primary outcomes of the review will include LGG management, morbidity and mortality. Secondary outcomes include epidemiology and recurrence of LGGs.
This scoping review will be the first to evaluate the current landscape of LGG management and outcomes in Africa, highlighting pertinent themes that may be used to guide further research as well as health system strengthening efforts by policymakers and stakeholders.
The protocol has been registered on the Open Science Framework (OSF; registration link: ).
LGGs account for 17% to 22% of total brain tumours and have a median survival time between 5.6 and 13.3 years.Despite many recent advancements in the management of LGGs, there is a paucity in the data within the African landscape.This scoping review will be the first to evaluate the current landscape of LGG management and outcomes in Africa, highlighting pertinent themes that may be used to guide further research and policymaking efforts.
在过去十年中，低级别胶质瘤（LGGs）的管理取得了许多进展。总体生存结果与术后残留体积等因素以及特定肿瘤生物分子特征（如异柠檬酸脱氢酶（IDH）突变状态）相关。目前尚不清楚这些进展是否使非洲的LGG患者受益。本范围综述方案概述了作者将如何评估非洲LGGs的流行病学、临床表现、管理和结局。
将检索MEDLINE、Embase和《非洲在线期刊》，从数据库建立至今，以识别相关研究。纳入在非洲国家接受治疗的所有年龄组、经组织学和/或放射学确诊为LGGs的患者。将考虑LGG肿瘤的手术和放化疗管理。将纳入原始研究、综述、评论、社论和病例报告。
综述的主要结局将包括LGG的管理、发病率和死亡率。次要结局包括LGGs的流行病学和复发情况。
本范围综述将首次评估非洲LGG管理和结局的现状，突出相关主题，这些主题可用于指导进一步研究以及政策制定者和利益相关者加强卫生系统的努力。
该方案已在开放科学框架（OSF；注册链接： ）上注册。
LGGs占脑肿瘤总数的17%至22%，中位生存时间在5.6至13.3年之间。尽管最近LGGs的管理取得了许多进展，但非洲地区的数据仍然匮乏。本范围综述将首次评估非洲LGG管理和结局的现状，突出相关主题，这些主题可用于指导进一步研究和政策制定工作。
